Skip to main content
Article
Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
Cancer Immunol Res
  • Winifred Lo
  • Maria Parkhurst
  • Paul F Robbins
  • Eric Tran
  • Yong-Chen Lu
  • Li Jia
  • Jared J Gartner
  • Anna Pasetto
  • Drew Deniger
  • Parisa Malekzadeh
  • Thomas E Shelton
  • Todd Prickett
  • Satyajit Ray
  • Scott Kivitz
  • Biman C Paria
  • Isaac Kriley
  • David S Schrump
  • Steven A Rosenberg
Document Type
Article
Publication Date
4-1-2019
Disciplines
Abstract

Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we report the identification and characterization in one patient of T-cell receptors (TCRs) recognizing mutated p53 p.R175H, which is shared among a subset of patients with cancer. Tumor-infiltrating lymphocytes were screened for recognition of mutated neoantigens in a patient with metastatic colorectal cancer. HLA-A*0201-restricted recognition of mutated p53 p.R175H was identified, and the minimal peptide epitope was HMTEVVR

Area of Special Interest
Cancer
Area of Special Interest
Digestive Health
Specialty/Research Institute
Earle A. Chiles Research Institute
Specialty/Research Institute
Oncology
Specialty/Research Institute
Gastroenterology
Citation Information
Winifred Lo, Maria Parkhurst, Paul F Robbins, Eric Tran, et al.. "Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer." Cancer Immunol Res (2019)
Available at: http://works.bepress.com/eric-tran/56/